Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors PR Newswire - Thu Dec 29, 2022

/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as...

BCAB : 1.6200 (-4.71%)
VTRS : 12.08 (+2.72%)
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress PR Newswire - Tue Nov 8, 2022

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 1.6200 (-4.71%)
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) PR Newswire - Mon Sep 12, 2022

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 1.6200 (-4.71%)
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress Globe Newswire - Tue Aug 9, 2022

Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the...

BCAB : 1.6200 (-4.71%)
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022 Globe Newswire - Tue Aug 2, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

BCAB : 1.6200 (-4.71%)
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress Globe Newswire - Wed May 4, 2022

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – – Mecbotamab vedotin (BA3011) Phase 2...

BCAB : 1.6200 (-4.71%)
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022 Globe Newswire - Fri Apr 8, 2022

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

BCAB : 1.6200 (-4.71%)

Barchart Exclusives

3 High Dividend Stocks Beginning To Breakout Off Their 52-Week Lows Barchart - Fri Jul 26, 6:00PM CDT
These stocks have recently hit their 52-week lows and are highly rated. Is now the time to buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot